Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

PURPOSE: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia de...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Stubbs, Matthew C., Kim, Wonil, Bariteau, Megan, Davis, Tina, Vempati, Sridhar, Minehart, Janna, Witkin, Matthew, Qi, Jun, Krivtsov, Andrei V., Bradner, James E., Kung, Andrew L., Armstrong, Scott A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433811/
https://ncbi.nlm.nih.gov/pubmed/25688158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1290
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk